Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that ADMA Biologics made false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors with losses in excess of $100,000 are encouraged to secure counsel before the deadline.
ADMA Biologics IncSecurities class action lawsuit alleging false statements, undisclosed related party transaction, channel stuffing, and inadequate internal controls.